No Wires, No Limits: A Bold Leap in Cardiac Tech
Institut Jantung Negara (IJN) has made history with a medical first for Southeast Asia. The team successfully implanted the Abbott AVEIR™ DR, the world's first dual-chamber leadless pacemaker. Approved by the US Food and Drug Administration (FDA) in 2023, this device is a game-changer for individuals with heart rhythm disorders.
'This groundbreaking dual-chamber leadless pacemaker will revolutionise care for our patients and significantly expand the number of people we can help,' said Dr Azlan, Senior Consultant Cardiologist and Clinical Director of Interventional Electrophysiology and Implantable Devices at IJN.
'By eliminating traditional wires (leads) and surgical pockets, the system reduces common complications such as infections, lead dislodgement, and vessel blockage.'
Designed for individuals with bradycardia (a slower-than-normal heart rate), AVEIR™ DR represents a significant leap in cardiac pacing. Unlike traditional pacemakers that rely on wires and are implanted under the skin, this system uses two tiny devices (each about one-tenth the size of a conventional pacemaker) implanted directly into the heart's right atrium and ventricle.
At the core of this advancement is Abbott's proprietary i2i™ (implant-to-implant) communication technology. This system uses high-frequency pulses conducted through the body's blood flow to synchronise the two pacemakers in real-time. It not only provides beat-to-beat coordination but also conserves battery life far more efficiently than Bluetooth® or radio frequency-based systems.
'This technology opens up new possibilities for patients with abnormal heart rhythms,' added Dr Azlan. 'It also allows real-time pacing analysis during implantation, enabling precise positioning and reducing procedural risks.'
At IJN, innovation is not just about adopting the latest medical devices—it's about improving patient outcomes. The successful use of the AVEIR™ DR system is a significant step forward for heart care in the region and further cements IJN's standing as a leader in cardiovascular medicine.
Cardiovascular disease continues to pose a serious challenge in Malaysia and across Southeast Asia. IJN's Chief Executive Officer, Prof. Datuk Sri Dr Mohamed Ezani Md Taib, emphasised the importance of early diagnosis, public awareness, and the integration of advanced medical solutions to achieve better patient outcomes.
Addressing media questions during a press conference, Dr Azlan addressed questions from the media about the long-term outcomes and potential limitations of the device. He noted that, based on over a decade of experience, the complication rate for leadless pacemakers remains very low—less than 1% in the short term and only slightly higher over the long term. The process of replacing the device when the battery is depleted is also simpler and safer, as there are no leads to remove.
As stated, the device is specifically intended for patients with confirmed slow or irregular heart rhythms, typically diagnosed through ECG or other monitoring tools. While pacemakers are not suitable for all heart rhythm disorders, IJN's team is committed to training doctors from across Malaysia and the region to expand access to this life-changing technology. Plans are also underway to collaborate with manufacturers on future innovations tailored to specific patient needs.
As with any new medical technology, cost remains a consideration. IJN is working to structure pricing that makes the device accessible to both public and private patients. The hospital's model of using private-sector revenue to subsidise public care will also help ensure broader access as the technology becomes more widely adopted.
As the world's first and only dual-chamber leadless pacemaker, the AVEIR™ DR represents a significant advancement in minimally invasive heart care. Its wire-free design reduces risks, enables quicker recovery, and allows for future upgrades—reflecting Abbott's vision to empower patients to live fuller, healthier lives. Related
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
Wild About Sprouts® Celebrates World Food Safety Day with Breakthrough Cold-Grown® Technology That Redefines Safety and Nutrition
SCOTTSDALE, Ariz., June 6, 2025 /PRNewswire/ — In honor of World Food Safety Day June 7, Wild About Sprouts® is shining a spotlight on its revolutionary Cold-Grown® process—an all-natural, patented innovation that has redefined food safety standards in the sprouting industry. With over 25 million containers sold pathogen-free and never part of any recall over its 8+ years, Wild About Sprouts is the only national sprout brand in the U.S., now proudly available in over 7,000 grocery stores across the country. Sprouts are among the most powerful, studied, and nutrient-dense superfoods on the planet. Yet for decades, their potential has been limited by persistent food safety concerns. Wild About Sprouts has solved that problem. Its Cold-Grown® process eliminates the risk of dangerous pathogens without the use of pesticides, herbicides, or chemical intervention, and uses 95% less water than traditional growing systems—making it one of the most sustainable solutions in fresh food today. 'At Wild About Sprouts, food safety isn't a feature—it's the foundation,' said Barry Didato, CEO of Rä Foods, parent company of Wild About Sprouts. 'Our patented Cold-Grown® method is changing the way America eats—combining breakthrough safety with unmatched nutrition, delivering sprouts that contain up to 100 times more antioxidants, vitamins, and minerals than fully grown vegetables. Backed by over 2,000 studies, sprouts—especially broccoli sprouts—are rich in sulforaphane, a proven compound that supports the body's natural detox pathways, helps fight cancer, reduces inflammation, and shows promise in managing conditions like autism, diabetes, and neurodegenerative disease.' Observed every year on June 7, World Food Safety Day highlights the importance of safe, accessible food for all. Wild About Sprouts is proud to lead this charge—proving that innovation can make clean, nutrient-packed, fresh foods not just possible, but scalable. 'Wild About Sprouts has not only innovated with its Cold-Grown® technology—they've demonstrated an uncompromising commitment to public health,' said Dr. Darin Detwiler, Food Safety Advocate, Professor and Author of Food Safety: Past, Present, and Predictions. 'In an era when consumers demand both transparency and accountability, this company offers a clear model of how science and responsibility can align to create safer, more sustainable food systems. As we recognize World Food Safety Day, this kind of leadership is precisely what our food system needs to move from reaction to prevention.' Whether tossed in a salad, layered on a sandwich, or blended into smoothies, Wild About Sprouts products offer an easy and delicious way to boost everyday nutrition—safely. For more information, visit or follow us on Instagram at @wild_about_sprouts. Wild About Sprouts is available at major retailers including Kroger, Walmart, Whole Foods Market, Sprouts Farmers Market, Albertsons, and many more. About Wild About Sprouts®Founded in 2016 and based in Scottsdale, Arizona, Wild About Sprouts is transforming the sprout industry with its science-backed, Cold-Grown® technology. As part of Rä Foods, a family office dedicated to better-for-you innovations, Wild About Sprouts is on a mission to deliver safe, delicious, nutrient-dense foods that Make America Healthy Again—one sprout at a time.
Malaysian Reserve
2 days ago
- Malaysian Reserve
Biodefense Market worth $1.81 billion by 2030
DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ — The biodefense market is projected to grow from USD 0.89 billion in 2025 to USD 1.81 billion by 2030 at a CAGR of 15.1% during the forecast period according to a new report by MarketsandMarkets™. The biodefense market is driven by increasing bioterrorism, growing geopolitical tensions, biological warfare risks, and advancements in technology. Biodefense encompasses a range of tools and systems designed to detect, prevent, and respond to biological threats, including infectious diseases, bioterrorism, and accidental pathogen releases. These include biosensors, rapid detection platforms, decontamination systems, mobile containment units, and AI-driven surveillance tools. The market for biodefense technology is experiencing strong growth due to increasing global concerns over pandemics, biological warfare, and emerging infectious diseases. Download PDF Brochure: Browse in-depth TOC on 'Biodefense Market' 196 – Tables56 – Figures217 – Pages Biodefense Market Report Scope: Report Coverage Details Market Revenue in 2025 $ 0.89 billion Estimated Value by 2030 $ 1.81 billion Growth Rate Poised to grow at a CAGR of 15.1% Market Size Available for 2020–2030 Forecast Period 2025–2030 Forecast Units Value (USD Million/Billion) Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends Segments Covered By Technology, Product, Application and Region Geographies Covered North America, Europe, Asia Pacific, and Rest of World Key Market Challenge Infrastructure constraints in low-resource areas Key Market Opportunities Emergence of AI-powered biosurveillance and predictive analytics Key Market Drivers Rising threat of Bioterrorism Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Based on application, the hospitals & medical institutes segment is expected to account for the largest share of the biodefense market during the forecast period. Hospitals are the initial point of contact for the identification of unusual infections or exposure to biological agents, and hence, they must have sophisticated containment systems, sterilization apparatus, and pathogen detection instruments in real time. With increasing bioterrorism, governments and health agencies are investing heavily in the upgrade of hospital biosafety facilities, such as Class III biological safety cabinets, mobile isolation units, and UV sterilization technology, all of which are becoming essential for modern biodefense infrastructure. These facilities need safe conditions to work with high-risk pathogens, which fuels the demand for low-temperature sterilizers, decontamination chambers, and air purification. The growing incorporation of digital surveillance platforms and smart biodefense technologies in healthcare facilities further solidifies their role in early detection and quick response, making hospitals & medical institutes the largest application segment of the biodefense market. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period. Based on technology, the AI technologies segment is projected to register the highest CAGR during the forecast period due to its significant contributions toward monitoring real-time pathogens, forecasting, and fast decision-making. AI facilitates the convergence and synthesis of large-scale environmental data and enables early threat detection and quick response coordination. Governments and health organizations globally are increasingly using AI platforms to track bio-threats across borders and to automatically report disease transmission for strategic purposes. Additionally, AI technologies are being integrated into biosensor networks, autonomous disinfecting robots, and predictive modeling applications utilized in hospitals, airports, and military bases. The increasing focus on digitally empowered biodefense infrastructure, coupled with significant investments by public and private sectors, is expected to fuel the growth of the AI segment in the global market. Inquiry Before Buying: Asia Pacific is projected to register the highest CAGR during the forecast period. Asia Pacific is projected to register the highest CAGR in the biodefense industry through the forecast period due to increasing investments in public health infrastructure, infectious disease surveillance, and military biosafety capacities. China, India, Japan, and Australia are comprehensively developing their biodefense capabilities. These countries are investing in mobile biosafety laboratories, near-real-time pathogen detection systems, and next-generation decontamination technologies to anticipate future biological threats. Also, the region is experiencing growth in biotechnology R&D, cross-border health security efforts, and government-backed biodefense programs. The growth of local biotech and med-tech firms is also propelling innovation in AI-powered disease monitoring, biosensors, and portable sterilizers for civilian and military applications. The growing population, susceptibility to zoonotic disease, and proactive policy changes are driving significant growth in the regional biodefense market. STERIS (US), ASP International GmbH (a subsidiary of Fortive) (US), Ushio Inc. (Japan), Sotera Health Company (US), and Bioquell, An Ecolab Solution (UK) are the major key players in the biodefense companies. These companies have strong distribution networks across regions like North America, Europe, Asia Pacific, and the Rest of the World. Get 10% Free Customization on this Report: Browse Adjacent Market: Aerospace and Defence Market Research Reports & Consulting Related Reports: Border Security Market by Domain (Land, Maritime, Airborne), Vertical (Military, Homeland Security), System (Surveillance Systems, Detection Systems, Communication Systems, Command and Control Systems), Installation & Region – Global Forecast to 2029 CBRN Defense Market by Type (Chemical, Biological, Radiological, Nuclear, Explosives), Equipment (Protective Wearables, Respiratory Systems, Detection & Monitoring Systems, Decontamination Systems, Simulators, Others), End Use and Region – Global Forecast to 2028 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Web Site: Insight: Source: Logo: View original content:
BusinessToday
3 days ago
- BusinessToday
No Wires, No Limits: A Bold Leap in Cardiac Tech
Institut Jantung Negara (IJN) has made history with a medical first for Southeast Asia. The team successfully implanted the Abbott AVEIR™ DR, the world's first dual-chamber leadless pacemaker. Approved by the US Food and Drug Administration (FDA) in 2023, this device is a game-changer for individuals with heart rhythm disorders. 'This groundbreaking dual-chamber leadless pacemaker will revolutionise care for our patients and significantly expand the number of people we can help,' said Dr Azlan, Senior Consultant Cardiologist and Clinical Director of Interventional Electrophysiology and Implantable Devices at IJN. 'By eliminating traditional wires (leads) and surgical pockets, the system reduces common complications such as infections, lead dislodgement, and vessel blockage.' Designed for individuals with bradycardia (a slower-than-normal heart rate), AVEIR™ DR represents a significant leap in cardiac pacing. Unlike traditional pacemakers that rely on wires and are implanted under the skin, this system uses two tiny devices (each about one-tenth the size of a conventional pacemaker) implanted directly into the heart's right atrium and ventricle. At the core of this advancement is Abbott's proprietary i2i™ (implant-to-implant) communication technology. This system uses high-frequency pulses conducted through the body's blood flow to synchronise the two pacemakers in real-time. It not only provides beat-to-beat coordination but also conserves battery life far more efficiently than Bluetooth® or radio frequency-based systems. 'This technology opens up new possibilities for patients with abnormal heart rhythms,' added Dr Azlan. 'It also allows real-time pacing analysis during implantation, enabling precise positioning and reducing procedural risks.' At IJN, innovation is not just about adopting the latest medical devices—it's about improving patient outcomes. The successful use of the AVEIR™ DR system is a significant step forward for heart care in the region and further cements IJN's standing as a leader in cardiovascular medicine. Cardiovascular disease continues to pose a serious challenge in Malaysia and across Southeast Asia. IJN's Chief Executive Officer, Prof. Datuk Sri Dr Mohamed Ezani Md Taib, emphasised the importance of early diagnosis, public awareness, and the integration of advanced medical solutions to achieve better patient outcomes. Addressing media questions during a press conference, Dr Azlan addressed questions from the media about the long-term outcomes and potential limitations of the device. He noted that, based on over a decade of experience, the complication rate for leadless pacemakers remains very low—less than 1% in the short term and only slightly higher over the long term. The process of replacing the device when the battery is depleted is also simpler and safer, as there are no leads to remove. As stated, the device is specifically intended for patients with confirmed slow or irregular heart rhythms, typically diagnosed through ECG or other monitoring tools. While pacemakers are not suitable for all heart rhythm disorders, IJN's team is committed to training doctors from across Malaysia and the region to expand access to this life-changing technology. Plans are also underway to collaborate with manufacturers on future innovations tailored to specific patient needs. As with any new medical technology, cost remains a consideration. IJN is working to structure pricing that makes the device accessible to both public and private patients. The hospital's model of using private-sector revenue to subsidise public care will also help ensure broader access as the technology becomes more widely adopted. As the world's first and only dual-chamber leadless pacemaker, the AVEIR™ DR represents a significant advancement in minimally invasive heart care. Its wire-free design reduces risks, enables quicker recovery, and allows for future upgrades—reflecting Abbott's vision to empower patients to live fuller, healthier lives. Related
